Cover Image
市場調查報告書

鮭魚抑鈣素的中國市場分析

Investigation Report on China Salmon Calcitonin Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333483
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
鮭魚抑鈣素的中國市場分析 Investigation Report on China Salmon Calcitonin Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 35 Pages
簡介

中國是擁有全球最大的骨質疏鬆症患者的國家,骨質疏鬆症患者和骨質低的患者數推算達到2億8000萬人。現在,中國國內有10種以上的骨質疏鬆症治療藥上市,不過,以含有鮭魚抑鈣素的前5名品項佔整體市場的80%以上。鮭魚抑鈣素自1997年上市,2005∼2014年以年複合成長率(CAGR) 17.7%的氣勢成長,到近幾年市場成長率降低。

本報告提供中國的鮭魚抑鈣素的市場相關分析、整體市場規模和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、今後的市場趨勢預測等調查評估。

第1章 鮭魚抑鈣素的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的鮭魚抑鈣素市場概況

  • 中國國內的鮭魚抑鈣素專利的申請、認證情形
  • 主要製造商
  • 市場規模

第3章 鮭魚抑鈣素銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的鮭魚抑鈣素市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的鮭魚抑鈣素市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 鮭魚抑鈣素的醫院用標準價格

  • Lisapharma S. p. A (義大利)
  • Beijing Sciecure Pharmaceutical Co., Ltd (商標名:Jinerli)
  • Beijing Shuanglu Pharmaceutical Co., Ltd (商標名:Gutongning)
  • Luye Pharma Group
  • 旭化成 (日本)
  • Novartis AG (法國) (商標名:Miacalcic)
  • Novartis AG (瑞士) (商標名:Miacalcic)
  • Qingdao GD Biotechnology Pharmaceutical Co., Ltd (商標名:Gairuining)

第7章 中國國內的鮭魚抑鈣素的主要製造商

  • Novartis AG (瑞士)
  • Luye Pharma Group
  • 旭化成 (日本)
  • Beijing Sciecure Pharmaceutical Co., Ltd
  • Qingdao GD Biotechnology Pharmaceutical Co., Ltd

第8章 中國的鮭魚抑鈣素市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506225

China has become the country with the largest number of osteoporosis patients. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China has exceeded 12% and that this figure among elders is over 50%, among which nearly 33% suffer from fracture. Some experts forecast that the number of osteoporosis patients and patients with low bone mass will rise to 280 million. Bone metabolism is mainly regulated by calcitonin, sex hormone, parathyroid hormone and active vitamin D. As endocrine disorder is the most important reason for the development of osteoporosis, calcium supplement alone can't prevent middle aged and elder people from osteoporosis effectively.

Currently, there are over ten kinds of osteoporosis drugs in the Chinese market. The TOP5 products for sales value in 2014 are zoledronic acid, salmon calcitonin, alendronate sodium, alfacalcidol and sodium ibandronate which take up a market share of over 80%, leaving less than 20% to the rest products. In 1994, Novartis's salmon calcitonin entered China under the trade name of Miacalcic and later salmon calcitonin made by Lisapharma S. p. A came into the Chinese market. The main dosage forms in the market are injection and spray. The domestic salmon calcitonin injection was first developed by Hebei Union Pharmaceutical in 1997 under the trade name of Bangruide, followed by products coming from more than ten local enterprises. Salmon calcitonin's annual sales value has realized a 17.7% CAGR during the period of 2005-2011 despite a fluctuation during the period of 2012-2014.

It is expected that there is still room for the salmon calcitonin market to grow in China.

Readers can get at least the following information from this report:

  • market size of salmon calcitonin in China
  • competitive landscape of salmon calcitonin in Chinese market
  • price of salmon calcitonin made by different enterprises in China
  • market outlook of salmon calcitonin in China

The author suggests the following groups of people purchase this report:

  • manufacturers of osteoporosis drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

  • 1.1. Related Concepts of Salmon Calcitonin
  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Salmon Calcitonin in China

  • 2.1. Patent and Approval Status of Salmon Calcitonin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Salmon Calcitonin in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Salmon Calcitonin in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Salmon Calcitonin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Salmon Calcitonin in Chinese Hospitals in 2014

  • 6.1. Lisapharma S. p. A (Italy)
  • 6.2. Beijing Sciecure Pharmaceutical Co., Ltd (Trade Name: Jinerli)
  • 6.3. Beijing Shuanglu Pharmaceutical Co., Ltd (Trade Name: Gutongning)
  • 6.4. Luye Pharma Group
  • 6.5. Asahi Kasei Corporation (Japan)
  • 6.6. Novartis AG (France) (Trade Name: Miacalcic)
  • 6.7. Novartis AG (Switzerland) (Trade Name: Miacalcic)
  • 6.8. Qingdao GD Biotechnology Pharmaceutical Co., Ltd (Trade Name: Gairuining)

7. Major Manufactures of Salmon Calcitonin in Chinese Market, 2010-2014

  • 7.1. Novartis AG (Switzerland)
  • 7.2. Luye Pharma Group
  • 7.3. Asahi Kasei Corporation (Japan)
  • 7.4. Beijing Sciecure Pharmaceutical Co., Ltd
  • 7.5. Qingdao GD Biotechnology Pharmaceutical Co., Ltd

8. Market Outlook of Salmon Calcitonin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Approval Information of Salmon Calcitonin in China
  • Chart Sales Status of Salmon Calcitonin in China, 2010-2014
  • Chart Sales Value of Salmon Calcitonin in China, 2010-2014
  • Chart Sales Value of Salmon Calcitonin in Some Regions in China, 2010-2014
  • Chart Sales Volume of Salmon Calcitonin in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Salmon Calcitonin for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Made by Beijing Sciecure in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Made by Asahi Kasei (Japan) in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Made by Luye in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Made by Novartis (France) in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Spral in China, 2010-2014
  • Chart Sales Value and Market Share of Salmon Calcitonin Injection in China, 2010-2014
  • Chart Price of Salmon Calcitonin Made by Lisapharma S. p. A (Italy) in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Beijing Sciecure Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Beijing Shuanglu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Luye Pharma Group in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Asahi Kasei Corporation (Japan) in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Novartis AG (France) in Some Chinese Cities in 2014
  • Chart Price of Salmon Calcitonin Made by Novartis AG (Switzerland) in Some Chinese Cities in 2014
Back to Top